Danaher (DHR) DIvidends Date & History

Key Takeaways

• Danaher pays a quarterly dividend of $0.40 per share, with a forward annual yield of 0.82%.
• Recent 25% increase from $0.32 underscores 13 consecutive years of dividend growth.
• Low payout ratio of 25.45% signals strong sustainability backed by robust free cash flow.
• Yield competitive versus life sciences peers like TMO (0.36%) and RVTY (0.30%).
• Next ex-dividend date was March 27, 2026, with payment on April 24, 2026.

Dividend Overview

Danaher Corporation (DHR), a leader in life sciences, diagnostics, and biotechnology tools, maintains a modest quarterly dividend policy. The company recently raised its payout to $0.40 per share from $0.32, announced on February 24, 2026, for shareholders of record March 27, 2026, payable April 24, 2026. This delivers a forward annualized dividend of $1.60 and a yield of 0.82%, with trailing yield at 0.66%. Danaher is not a high-yield stock but qualifies as a dividend growth stock, prioritizing reinvestment in high-margin businesses while steadily rewarding shareholders. Its five-year average yield stands at 0.42%, reflecting a conservative yet progressive approach in a growth-oriented sector.

Dividend History and Growth

Danaher has demonstrated consistent dividend growth, achieving 13 consecutive annual increases. Recent history shows quarterly payments of $0.32 through 2025 (ex-dates June 27, September 26, December 26), jumping 25% to $0.40 in early 2026. Over the past decade, payouts have compounded at double-digit rates on average, aligning with the company's strategy of deploying capital across acquisitions and R&D in life sciences and diagnostics. No cuts have occurred, underscoring payment reliability amid cyclical industry dynamics.

Dividend Sustainability and Payout Ratio

Danaher's dividend appears highly sustainable, with a payout ratio of 25.45% leaving ample room for growth and reinvestment. Earnings per share comfortably cover dividends, supported by trailing twelve-month EPS around $5.02. Free cash flow generation remains robust, with non-GAAP FCF of $1.8 billion in Q4 2025 alone, far exceeding annual dividend obligations. Balance sheet strength, including manageable debt and high operating margins near 18%, bolsters coverage. This conservative profile mitigates risks in biotech and diagnostics cycles.

Dividend Compared to Industry Peers

In the life sciences and diagnostics sector, Danaher's 0.82% forward yield outpaces key peers. TMO offers 0.36%, RVTY 0.30%, and WAT pays none, reflecting growth priorities over income. Agilent (A) matches closely at 0.84%. Danaher's profile—low yield but superior growth and coverage—positions it favorably for investors seeking balanced exposure versus pure high-yield alternatives like ABT (2.60%).

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It excels at identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research workflow.

Is This Stock Attractive for Dividend Investors?

Danaher Corporation appeals to dividend growth investors prioritizing long-term compounding over immediate income, given its modest 0.82% yield and impressive 13-year streak of raises, including a recent 25% hike. Conservative investors may appreciate the low 25% payout ratio and strong free cash flow coverage, providing a margin of safety in the volatile life sciences sector. Those seeking total returns through capital appreciation alongside modest dividends will find alignment, as Danaher reinvests heavily in high-growth areas like bioprocessing and diagnostics. However, high-yield seekers may look elsewhere, as the profile suits patient, growth-oriented portfolios rather than pure income strategies. Balanced analysis reveals suitability for diversified holdings emphasizing quality and sustainability over top-tier yields.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations